TSS
VVOS icon

Two Sigma Securities’s Vivos Therapeutics VVOS Stock Holding History

Two Sigma Securities’s Portfolio VVOS Stock Details VVOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-495
Closed -$6.32K – 3538
2023
Q2 		$6.32K Buy
+495
New +$4.85K ﹤0.01% 2649
2023
Q1 		– Sell
-489
Closed -$4.91K – 3331
2022
Q4 		$4.91K Buy
+489
New +$7.15K ﹤0.01% 2452

Other funds holding VVOS

SWIG
Strategic Wealth Investment Group Louisville, Kentucky $788M AUM 14.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AF
Apexium Financial Dallas, Texas $2.06B AUM 15.96% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Two Sigma Securities's VVOS Position: Q3 2023 in Review

Two Sigma Securities sold out of Vivos Therapeutics (VVOS) in Q3 2023, closing a stake of 495 shares — an estimated $6.32K sold.

Two Sigma Securities first reported a position in VVOS in Q4 2022 and held it in 2 quarters. The position peaked at $6.32K in Q2 2023. 28 funds tracked by Wall St. Rank hold VVOS as of Q3 2023.

  • Two Sigma Securities reported no remaining Vivos Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Two Sigma Securities sold 495 Vivos Therapeutics shares in Q3 2023, an estimated $6.32K.
  • Two Sigma Securities first reported a position in Vivos Therapeutics in Q4 2022 and held it in 2 quarters.
  • Two Sigma Securities's Vivos Therapeutics position peaked at $6.32K in Q2 2023.
  • 28 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q3 2023.

Based on Two Sigma Securities's 13F filing for Q3 2023, filed 14 Nov 2023.